Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Trellus Health PLC ( (GB:TRLS) ).
Trellus Health PLC announced its audited results for the year ended December 31, 2024, highlighting significant operational and financial developments. The company signed key agreements with a large US national health plan and pharmaceutical companies, emphasizing its focus on expanding commercial partnerships and clinical trial research. Despite an adjusted EBITDA loss of $7.2 million, Trellus Health extended its cash runway into October 2025 and is actively seeking additional funding. The company launched a pilot program with Johnson & Johnson to support patients with IBD, showcasing the potential of its Trellus Elevate® platform. However, the need for further funding before October 2025 presents a material uncertainty regarding its ongoing operations.
More about Trellus Health PLC
Trellus Health PLC is a healthcare technology company specializing in innovative, scientifically validated programs and technologies aimed at improving the management of chronic conditions. The company offers a proprietary digital resilience platform, Trellus Elevate®, which focuses on bridging the gap between mental and physical health impacts of chronic conditions, particularly in gastrointestinal disorders like Inflammatory Bowel Disease (IBD). Trellus Health’s approach is designed to enhance patient engagement, adherence, and outcomes while reducing healthcare costs.
Average Trading Volume: 556,096
Technical Sentiment Signal: Sell
Current Market Cap: £2.91M
For detailed information about TRLS stock, go to TipRanks’ Stock Analysis page.